Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer

Drug Delivery

Carolina Negrei¹  Mikhail Shtilman²  Sabina Georgiana Nitu³  Octav Ginghina⁴  Catalin Zaharia⁵  Ionut Cristian Radu⁵  Horia Iovu⁵  Eugenia (Vasile) Tanasa⁵  Bianca Galateanu⁶  Marieta Costache⁶  Ariana Hudita⁶  Aristidis Tsatsakis⁷  Kelly Velonia⁷ 

[1] Carol Davila University of Medicine and Pharmacy;D.I. Mendeleyev University of Chemical Technology;National Research and Development Institute for Chemistry and Petrochemistry – ICECHIM;Sf. Ioan Emergency Clinical Hospital;University Politehnica of Bucharest;University of Bucharest;University of Crete;

关键词: nanocarrier;    5-fu;    polyhydroxyalkanoate;    ht-29;    colorectal cancer;    anticancer efficacy;   

DOI  :  10.1080/10717544.2019.1582729

来源: DOAJ

【 摘 要 】

Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) carriers were obtained via the emulsification-diffusion method, loaded with 5-fluorouracil and then characterized in terms of particle morphology and size (SEM, DLS), drug uptake and release. The cytotoxic potential of the 5-fluorouracil-loaded polymer nanocarriers on human adenocarcinoma cells (HT-29 cell line) was investigated. The in vitro studies clearly demonstrated that while the nanocarriers themselves slightly alter HT-29 cell viability, when loaded with 5-fluorouracil they significantly decrease cell viability, suggesting that the polymer itself exhibits low cytotoxicity and the drug-loaded carrier acts in an efficient manner to kill HT-29 human adenocarcinoma cells.

【 授权许可】

Unknown